Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Multiple myeloma
Feasibility/Early Phase 1 iberdomide (CC-220) cereblon E3-ligase modulator primes T cells
This single-site feasibility study tests whether a 28-day “priming” cycle of iberdomide before leukapheresis can improve T-cell fitness and, downstream, CAR-T expansion kinetics in relapsed/refractory multiple…
NCT07727668 Exploratory - New trial
Multiple myeloma
Phase 4 linvoseltamab BCMA×CD3 bispecific with prophylactic tocilizumab IL-6R blockade
Regeneron Pharmaceuticals is running this Phase 4, single-arm, multicenter outpatient study testing whether giving tocilizumab prophylactically before the first linvoseltamab dose can reduce cytokine release syndrome…
NCT07609940 Exploratory - New trial
Pancreatic cancer
Phase 2 telisotuzumab adizutecan (ABBV-400) c-Met/HGFR ADC with topoisomerase payload
AbbVie’s AndroMETa-118 (NCT07769502; AbbVie study M26-118) is a Phase 2, open-label master protocol in pancreatobiliary cancers testing telisotuzumab adizutecan (ABBV‑400), a c‑Met/HGFR–directed monoclonal…
NCT07769502 Exploratory - New trial
Prostate cancer
MR-guided focal SBRT uses MRI target localization to deliver high-dose hypofractionated radiation.
This City of Hope Medical Center pilot evaluates focal magnetic resonance–guided stereotactic body radiation therapy (MR-guided SBRT), a device-enabled radiation approach (not a drug) that uses on-table MRI to…
NCT07769372 Exploratory - New trial Spotlight
Head and neck cancer
Phase 3 CRB-701 nectin-4–targeted ADC (MMAE tubulin inhibitor) vs chemo/EGFR options in R/M OPSCC
Corbus Pharmaceuticals’ TEMPO-1 is a randomized, open-label, 2-arm Phase 3 trial testing CRB-701 (also referenced as SYS6002), a nectin-4–directed monoclonal antibody–drug conjugate that delivers the microtubule…
NCT07768189 Registrational - New trial Spotlight
Colorectal cancer
Phase 2 ivonescimab PD-1×VEGF bispecific antibody plus intraperitoneal paclitaxel chemotherapy
MD Anderson Cancer Center is running this Phase 2, single-arm study testing ivonescimab (a PD-1 and VEGF-targeted bispecific antibody; developed by Akeso Biopharma and partnered by Summit Therapeutics) combined with…
NCT07753824 Exploratory - New trial
Ovarian cancer
Phase 1 arginine supplementation metabolic immunomodulator with pembrolizumab PD-1 blockade in PROC
This open-label, non-randomized Phase 1 study tests whether supplemental L-arginine (oral and/or IV) can safely be added to common chemoimmunotherapy backbones for high-grade, platinum-resistant ovarian/fallopian…
NCT07772882 Exploratory - New trial
Breast cancer
Phase 2 romosozumab sclerostin-directed monoclonal antibody as bone-anabolic therapy in bone-metastatic ER/PR+ breast cancer
Memorial Sloan Kettering Cancer Center is running REMOLD-Breast (Phase 2) to test whether romosozumab (Evenity; Amgen/UCB)—a sclerostin-neutralizing monoclonal antibody that increases bone formation and also reduces…
NCT07776613 Exploratory - New trial
Small cell lung cancer
Phase 3 tarlatamab (Amgen) DLL3×CD3 bispecific T‑cell engager compares SC vs IV dosing
Amgen’s DeLLphi-315 is a Phase 3, open-label, randomized, multicenter study in relapsed extensive-stage small cell lung cancer (ES-SCLC) after platinum-based first-line chemotherapy. Participants are randomized to…
NCT07778316 Exploratory - New trial Spotlight
Acute myeloid leukemia and MDS
Phase 2/3 Pivekimab sunirine CD123-targeted ADC (IGN payload) + venetoclax/azacitidine in AML
AbbVie’s randomized Phase 2/3 trial (NCT07581002) tests whether adding pivekimab sunirine (PVEK)—a CD123-directed monoclonal antibody–drug conjugate carrying an indolinobenzodiazepine (IGN) DNA-alkylating payload—can…
NCT07581002 Registrational - New trial
Lymphoma
Phase 2 tafasitamab CD19 cytolytic mAb + rituximab CD20 mAb in untreated follicular lymphoma
This University of Washington–sponsored Phase 2, single-arm study (with Incyte Corporation collaboration) tests whether adding tafasitamab to rituximab can deepen first-remission quality in newly diagnosed follicular…
NCT07731789 Exploratory - New trial
Chronic lymphocytic leukemia
Phase 2 venetoclax (BCL-2 inhibitor) + zanubrutinib (BTK inhibitor) in CLL/SLL
This Phase 2 study evaluates a time-staggered oral doublet—zanubrutinib first, then venetoclax added starting cycle 4—to deepen responses and reduce measurable residual disease in chronic lymphocytic leukemia/small…
NCT07734038 Exploratory - New trial Spotlight
Liver and bile duct cancer
Phase 2a pemigatinib FGFR1/2/3 inhibitor alternated with durvalumab PD‑L1 blockade
This Ohio State University Comprehensive Cancer Center Phase 2a study tests a “cyclical/alternating” first-line strategy for unresectable, locally advanced, or metastatic biliary tract cancers (commonly intrahepatic…
NCT07780838 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 1b monzosertib CDC7 kinase inhibitor tests azole–drug interaction dosing in AML/MDS
MD Anderson Cancer Center is running this Phase 1b, open-label, investigator-initiated study to define the recommended Phase 2 dose of monzosertib, a small-molecule CDC7 (cell-division cycle 7) kinase inhibitor that…
NCT07780565 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 1 arsenic trioxide p53-reactivating agent with fludarabine/busulfan allo-HSCT in AML/MDS
University of Michigan Rogel Cancer Center is running this Phase 1, non-randomized study testing whether adding arsenic trioxide (ATO)—a small molecule reported to help restore wild-type conformation/function of some…
NCT07737769 Exploratory - New trial
Multiple solid tumors
TriNav pressure-enabled infusion catheter (pressure-modulated delivery) for Y-90 resin microspheres
Stanford University’s PRESSURE trial is a prospective, randomized, within-patient study testing whether pressure-modulated intra-arterial delivery improves Y-90 resin microsphere deposition in liver metastases…
NCT07791446 Exploratory - New trial
Multiple solid tumors
Phase 2 OAT ICI tests COX inhibition + H1 antihistamine modulation alongside ICIs
This Phase 2, single-site interventional study at University of Kentucky/Markey Cancer Center evaluates whether “optimizing” common ancillary meds can improve outcomes for patients with radiographically measurable…
NCT07661459 Exploratory - New trial
Multiple solid tumors
Phase 1 GS-1206 small-molecule inhibitor tests undisclosed target in advanced solid tumors.
No disclosed MOA. We do not include details of trials without this basic information.
NCT07703878 First-in-human - Trial result
Prostate cancer
Enzalutamide (AR inhibitor) + testosterone suppression extends 8-year OS in mHSPC vs first-gen NSAAs (ENZAMET)
Enzalutamide is a potent androgen receptor (AR) signaling inhibitor, and in the ENZAMET Phase 3 trial (NCT02446405) it was added to testosterone suppression (ADT) and compared against ADT + a first-generation…
NCT02446405 - Trial result Spotlight
Lymphoma
Epcoritamab (CD3×CD20 bispecific) + R-CHOP Drives 85% CR and 80% 2-year PFS in High-Risk Newly Diagnosed LBCL
Epcoritamab is a subcutaneous CD3×CD20 bispecific T-cell–engaging antibody added to standard R-CHOP, aiming to deepen frontline remissions in CD20+ large B-cell lymphoma (LBCL). In Arm 1 of the Phase 1b/2 EPCORE…
NCT04663347 - Trial result
Lymphoma
Glofitamab (CD20×CD3 bispecific) + G/R-CHOP drives 83.9% complete metabolic responses in R/R B-cell NHL
Glofitamab is an IV CD20×CD3 T-cell–engaging bispecific antibody; here it was combined with obinutuzumab/rituximab plus CHOP (G/R-CHOP) in a Phase 1b dose-escalation study in relapsed/refractory B-cell non-Hodgkin…
NCT03467373 - Trial result
Breast cancer
THP (taxane + trastuzumab/pertuzumab) posts 43.8% pCR in stage II/IIIa HER2+ breast cancer—63.7% in ER− vs 32.4% in ER+
EA1181/CompassHER2 pCR (NCT04266249) tested neoadjuvant THP: 4 cycles of trastuzumab + pertuzumab with either weekly paclitaxel (12 weeks) or q3w docetaxel (x4), then surgery, in clinical stage II/IIIa HER2+ breast…
NCT04266249 - Trial result
Bladder and urothelial cancer
pT3–4/pN+/pT2+LVI model flags ~4× higher post-cystectomy recurrence risk, guiding longer-intense surveillance
In a retrospective European individual-patient registry study of 3196 patients with cT2–T4 N0M0 bladder cancer treated with radical cystectomy across 16 centers (1990–2024), investigators used a Classification and…
- Trial result Spotlight
Head and neck cancer
TG4050 (individualized MVA neoantigen vaccine) shows 0/16 per-protocol relapses at 30 months in resected HPV-negative HNSCC
TG4050 is a personalized therapeutic cancer vaccine delivered through a Modified Vaccinia Ankara (MVA) vector encoding up to 30 patient-specific predicted neoantigens to generate tumor-directed T-cell immunity. In…
NCT04183166 - Trial result
Acute lymphoblastic leukemia
MRD ≥0.01% Before or Day 100 Post-HSCT Flags Higher Relapse Risk in Pediatric ALL
Measurable residual disease (MRD) ≥0.01% identified a substantially higher-risk group among 1,014 children and young adults (ages 4–21) receiving matched-donor allogeneic HSCT in the extended international FORUM…
NCT01949129 - Trial result Spotlight
Colorectal cancer
Sotorasib (KRAS G12C inhibitor) + panitumumab (EGFR mAb) + FOLFIRI drives 56.5% ORR in pretreated KRAS G12C mCRC
Sotorasib is an oral covalent KRAS G12C inhibitor and panitumumab is an EGFR-targeting monoclonal antibody; here they were combined with irinotecan/leucovorin/5-FU (FOLFIRI) in the CodeBreaK 101 Phase 1b subprotocol…
NCT04185883 - New trial Spotlight
Pancreatic cancer
Phase 1b/2 ANO31905 CLDN18.2×CD3 bispecific + chemo in first-line PDAC
This open-label, nonrandomized Phase 1b/2 study (n=84) tests two dose levels of ANO31905 plus gemcitabine and nab-paclitaxel in untreated CLDN18.2-positive locally advanced unresectable or metastatic pancreatic…
NCT07444541 Exploratory - New trial
Pancreatic cancer
Phase 2 vilastobart tumor-activated Fc-enhanced anti-CTLA-4 plus retifanlimab PD-1 blockade in HRD PDAC.
This Phase 2, single-arm, open-label study (EKLAVYA-HRD) tests dual immune checkpoint blockade using vilastobart (XTX101)—a tumor-activated, Fc‑enhanced anti‑CTLA‑4 antibody designed to preferentially activate in the…
NCT07765836 Exploratory - New trial
Pancreatic cancer
Phase 2 SMART-PANC tests SMAD4-guided neoadjuvant chemo (DNA synthesis/tubulin inhibitors) in PDAC
Northwestern University is running this single-center, non-randomized Phase 2 pilot in resectable and borderline-resectable pancreatic ductal adenocarcinoma (PDAC) to see whether pre-treatment SMAD4 status can be…
NCT07748611 Exploratory - New trial Spotlight
Prostate cancer
Phase 2 MRT-2359 GSPT1 molecular glue degrader + apalutamide AR inhibitor in AR-mutant mCRPC.
This Phase 2 open-label, multicenter study (MODeFIRe-1) from Monte Rosa Therapeutics tests oral MRT-2359 plus apalutamide in patients with castration-resistant prostate adenocarcinoma whose tumors harbor androgen…
NCT07745361 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.